JP2017528460A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528460A5
JP2017528460A5 JP2017512975A JP2017512975A JP2017528460A5 JP 2017528460 A5 JP2017528460 A5 JP 2017528460A5 JP 2017512975 A JP2017512975 A JP 2017512975A JP 2017512975 A JP2017512975 A JP 2017512975A JP 2017528460 A5 JP2017528460 A5 JP 2017528460A5
Authority
JP
Japan
Prior art keywords
cancer
cell
tumor
lymphoma
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528460A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049231 external-priority patent/WO2016040511A1/en
Publication of JP2017528460A publication Critical patent/JP2017528460A/ja
Publication of JP2017528460A5 publication Critical patent/JP2017528460A5/ja
Pending legal-status Critical Current

Links

JP2017512975A 2014-09-10 2015-09-09 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド Pending JP2017528460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048760P 2014-09-10 2014-09-10
US62/048,760 2014-09-10
PCT/US2015/049231 WO2016040511A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamides as irreversible smyd inhibitors

Publications (2)

Publication Number Publication Date
JP2017528460A JP2017528460A (ja) 2017-09-28
JP2017528460A5 true JP2017528460A5 (enExample) 2018-10-25

Family

ID=55459533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512975A Pending JP2017528460A (ja) 2014-09-10 2015-09-09 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド

Country Status (6)

Country Link
US (2) US10179773B2 (enExample)
EP (1) EP3193606B1 (enExample)
JP (1) JP2017528460A (enExample)
AU (1) AU2015315180A1 (enExample)
CA (1) CA2960279A1 (enExample)
WO (1) WO2016040511A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム,インコーポレイティド イソオキサゾールカルボキサミド化合物
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN115998869B (zh) * 2022-09-23 2025-08-05 华中科技大学同济医学院附属同济医院 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用
IT202200021138A1 (it) * 2022-10-13 2024-04-13 Istituto Di Ricovero E Cura A Carattere Scient Saverio De Bellis Formulati farmaceutici con attività inibente le metiltrasferasi istoniche per il trattamento di patologie neoplastiche

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
CN1528745A (zh) * 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
JP2017526706A (ja) * 2014-09-10 2017-09-14 エピザイム,インコーポレイティド イソオキサゾールカルボキサミド化合物
AU2015315171A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
MX2017002986A (es) * 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
US20170247326A1 (en) 2014-09-10 2017-08-31 Epizyme, Inc. Substituted Pyrrolidine Carboxamide Compounds
US20170253601A1 (en) 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Similar Documents

Publication Publication Date Title
JP2017528460A5 (enExample)
RU2018138735A (ru) Деструкторы белка mdm2
JP2016514695A5 (enExample)
JP2017528464A5 (enExample)
JP2017538659A5 (enExample)
JP2017526706A5 (enExample)
JP2017527577A5 (enExample)
JP2019514950A5 (enExample)
CY1121661T1 (el) Παραγωγα πυριδονης ως αναστολεις της αναδιαταγμενης κατα τη διαμολυνση (ret) κινασης
Kodaz et al. Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer
JP2017527576A5 (enExample)
MX2017003118A (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
MA38394A1 (fr) Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
JP2017528461A5 (enExample)
Park et al. Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D
JP2009515851A5 (enExample)
IL272697B1 (en) A polymorphic form of tg02
Sharma et al. ErbBs in lung cancer
RU2016118008A (ru) Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака
EA200901538A1 (ru) Замещенные пирролопиридины и пиразолопиридины в качестве модуляторов киназ
JP2020515571A5 (enExample)
FI4053128T3 (fi) 5-(2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)-3-(1h-pyratsol-1-yyli)pyratsolo[1,5-a]pyrimidiinijohdannaisia ja niihin liittyviä yhdisteitä trk-kinaasinhibiittoreina syövän hoitoon
JPWO2021188948A5 (enExample)
UY32822A (es) Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.